Findings

What do systematic reviews say?

5 questions · 7 findings · 1 reviews · Gut

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 5 · 71.4%High 1 · 14.3%

Failure to maintain remission · people with moderate to severe Crohn's disease in remission

Ustekinumab showed no clear difference in failure to maintain clinical remission compared with placebo (moderate certainty).

2 findings from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.8 [0.63, 1.02]
1 study · 145 participants
Moderate
Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.76 [0.64, 0.91]
1 study · 388 participants
Moderate

Failure to maintain clinical response · people with moderate to severe Crohn's disease in remission

Ustekinumab probably leads to lower failure to maintain clinical response compared with placebo (moderate certainty).

2 findings from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.53 [0.36, 0.79]
1 study · 145 participants
Moderate
Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.74 [0.6, 0.91]
1 study · 388 participants
Moderate

Adverse events · people with moderate to severe Crohn's disease in remission

Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.94 [0.87, 1.03]
2 studies · 541 participants
High

Serious adverse events · people with moderate to severe Crohn's disease in remission

Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.74 [0.48, 1.15]
2 studies · 541 participants
Moderate

Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission

Ustekinumab showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 4.93 [0.59, 41.18]
1 study · 145 participants
Low